Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Novo Nordisk A/S stock
Learn how to easily invest in Novo Nordisk A/S stock.
Novo Nordisk A/S is a biotechnology business based in the US. Novo Nordisk A/S shares (NVO) are listed on the NYSE and all prices are listed in US Dollars. Novo Nordisk A/S employs 50,816 staff and has a trailing 12-month revenue of around $157.3 billion.
How to buy shares in Novo Nordisk A/S
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – NVO – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Novo Nordisk A/S stock price (NYSE: NVO)Use our graph to track the performance of NVO stocks over time.
Novo Nordisk A/S shares at a glance
|Latest market close||$99.63|
|52-week range||$90.40 - $121.50|
|50-day moving average||$105.89|
|200-day moving average||$107.13|
|Wall St. target price||$126.42|
|Dividend yield||$11.15 (1.61%)|
|Earnings per share (TTM)||$2.88|
Buy Novo Nordisk A/S shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Novo Nordisk A/S stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Novo Nordisk A/S price performance over time
|1 week (2022-09-27)||3.89%|
|1 month (2022-09-02)||-2.55%|
|3 months (2022-07-01)||-10.76%|
|6 months (2022-04-04)||-12.46%|
|1 year (2021-10-04)||2.77%|
|2 years (2020-10-02)||45.11%|
|3 years (2019-10-04)||94.13%|
|5 years (2017-10-04)||102.17%|
Is Novo Nordisk A/S stock undervalued or overvalued?
Valuing Novo Nordisk A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novo Nordisk A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Novo Nordisk A/S's P/E ratio
Novo Nordisk A/S's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Novo Nordisk A/S shares trade at around 35x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Novo Nordisk A/S's PEG ratio
Novo Nordisk A/S's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7345. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novo Nordisk A/S's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Novo Nordisk A/S's EBITDA
Novo Nordisk A/S's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $72 billion.
The EBITDA is a measure of a Novo Nordisk A/S's overall financial performance and is widely used to measure a its profitability.
Novo Nordisk A/S financials
|Revenue TTM||$157.3 billion|
|Operating margin TTM||42.68%|
|Gross profit TTM||$117.1 billion|
|Return on assets TTM||22.25%|
|Return on equity TTM||72.19%|
|Market capitalisation||$225.4 billion|
TTM: trailing 12 months
Novo Nordisk A/S share dividends
Dividend payout ratio: 7.24% of net profits
Recently Novo Nordisk A/S has paid out, on average, around 7.24% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.61% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novo Nordisk A/S shareholders could enjoy a 1.61% return on their shares, in the form of dividend payments. In Novo Nordisk A/S's case, that would currently equate to about $11.15 per share.
While Novo Nordisk A/S's payout ratio might seem low, this can signify that Novo Nordisk A/S is investing more in its future growth.
Novo Nordisk A/S's most recent dividend payout was on 22 August 2022. The latest dividend was paid out to all shareholders who bought their shares by 11 August 2022 (the "ex-dividend date").
Have Novo Nordisk A/S's shares ever split?
Novo Nordisk A/S's shares were split on a 5:1 basis on 8 January 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Novo Nordisk A/S shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Novo Nordisk A/S shares which in turn could have impacted Novo Nordisk A/S's share price.
Novo Nordisk A/S share price volatility
Over the last 12 months, Novo Nordisk A/S's shares have ranged in value from as little as $90.4 up to $121.5047. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novo Nordisk A/S's is 0.2894. This would suggest that Novo Nordisk A/S's shares are less volatile than average (for this exchange).
Novo Nordisk A/S overview
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease.
Novo Nordisk A/S in the news
Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes
Will Acquisitions Help Novo Nordisk (NVO) Combat Stiff Rivalry?
Novo Nordisk A/S – Share repurchase programme
Frequently asked questionsWhat percentage of Novo Nordisk A/S is owned by insiders or institutions?
Currently 0.007% of Novo Nordisk A/S shares are held by insiders and 8.671% by institutions. How many people work for Novo Nordisk A/S?
Latest data suggests 50,816 work at Novo Nordisk A/S. When does the fiscal year end for Novo Nordisk A/S?
Novo Nordisk A/S's fiscal year ends in December. Where is Novo Nordisk A/S based?
Novo Nordisk A/S's address is: Novo Allé 1, Bagsvaerd, Denmark, 2880 What is Novo Nordisk A/S's ISIN number?
Novo Nordisk A/S's international securities identification number is: US6701002056 What is Novo Nordisk A/S's CUSIP number?
Novo Nordisk A/S's Committee on Uniform Securities Identification Procedures number is: 670100205
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert